the aid library

LIST OPTIONS

Filter

3914

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (107)

View PDF (94)

Mpox Testing Strategy - November 2024

Africa Center for Disease Control and Prevention (2024) CC

Mpox is an emerging zoonotic disease caused by the mpox virus, a member of the Orthopoxvirus genus closely related to the variola virus that causes smallpox. Mpox was first discovered in 1958 when outbreaks of a pox-like disease occurred in monkeys kept for research. The first human case was recorde...d in 1970 in the Democratic Republic of the Congo (DRC) during a period of intensified effort to eliminate smallpox and since then the infection has been reported in a number of African countries. Mpox can spread in humans through close contact, usually skin-to-skin contact, including sexual contact, with an infected person or animal, as well as with materials contaminated with the virus such as clothing, beddings and towels, and respiratory droplets in prolonged face to face contact. People remain infectious from the onset of symptoms until all the lesions have scabbed and healed. The virus may spread from infected animals through handling infected meat or through bites or scratches. Diagnosis is confirmed by polymerase chain reaction (PCR) testing of material from a lesion for the virus’s DNA. Two separate clades of the mpox virus are currently circulating in Africa: Clade I, which includes subclades Ia and Ib, and Clade II, comprising subclades IIa and IIb. Clade Ia and Clade Ib have been associated with ongoing human-to-human transmission and are presently responsible for outbreaks in the Democratic Republic of the Congo (DRC), while Clade Ib is also contributing to outbreaks in Burundi and other countries. In 2022‒2023 mpox caused a global outbreak in over 110 countries, most of which had no previous history of the disease, primarily driven by human-to-human transmission of clade II through sexual contact. In just over a year, over 90,000 cases and 150 deaths were reported to the WHO. For the second time since 2022, mpox has been declared a global health emergency as the virus spreads rapidly across the African continent. On 13 Aug 2024, Africa CDC declared the ongoing mpox outbreak a Public Health Emergency of Continental Security (PHECS), marking the first such declaration by the agency since its inception in 2017.7 This declaration empowered the Africa CDC to lead and coordinate responses to the mpox outbreak across affected African countries. On August 14, 2024, the WHO declared the resurgence of mpox a Public Health Emergency of International Concern (PHEIC) emphasizing the need for coordinated international response. As of August 2024, Mpox has expanded beyond its traditional endemic regions, with new cases reported in countries including Sweden, Thailand, the Philippines, and Pakistan. Sweden has confirmed its first case of Clade 1 variant, which has been rapidly spreading in Africa, particularly in DRC. The emergence of this new variant raises concerns about its potential for higher lethality and transmission rates outside Africa. more

Download (207)

View PDF (179)

Strategic Framework for Enhancing Prevention and Control of mpox, 2024-2027

World Health Organization WHO (2024) C_WHO

Mpox continues to affect people around the world. A new framework released today by WHO will guide health authorities, communities and other stakeholders in preventing and controlling mpox outbreaks, eliminating human-to-human transmission of the disease, and reducing spillover of the virus from ani... more

Download (46)

View PDF (32)

Africa’s Health Financing in a New Era

Africa Centres for Disease Control and Prevention (Africa CDC) (2025) CC

Africa’s health sector is facing an unprecedented financing crisis, driven by a sharp decline of 70% in Official Development Assistance (ODA) from 2021 to 2025 and deep-rooted structural vulnerabilities. This collapse is placing immense pressure on Africa’s already fragile health systems as ODA ...is seen as the backbone of critical health programs: pandemic preparedness, maternal and child health services, disease control programs are all at risk, threatening Sustainable Development Goal 3 and Universal Health Coverage. Compounding this is Africa’s spiraling debt, with countries expected to service USD 81 billion by 2025—surpassing anticipated external financing inflows—further eroding fiscal space for health investments. Level of domestic resources is low. TThe Abuja Declaration of 2001, a pivotal commitment made by African Union (AU) member states, aimed to reverse this trend by pledging to allocate at least 15% of national budgets to the health sector. However, more than two decades later, only three countries—Rwanda, Botswana, and Cabo Verde—have consistently met or exceeded this target (WHO, 2023). In contrast, over 30 AU member states remain well below the 10% benchmark, with some allocating as little as 5–7% of their national budgets to health. In addition, only 16 (29%) of African countries currently have updated versions of National Health Development Plan (NHDP) supported by a National Health Financing Plan (NHFP). These two documents play a critical role in driving internal resource mobilisation. At the same time, public health emergencies are surging, rising 41%—from 152 in 2022 to 213 in 2024—exposing severe under-resourcing of health infrastructure and workforce. Recurring outbreaks (Mpox, Ebola, cholera, measles, Marburg…) alongside effects of climate change and humanitarian crises in Eastern DRC, the Sahel, and Sudan, are overwhelming systems stretched by chronic underfunding. The situation is worsened by Africa’s heavy dependency with over 90% of vaccines, medicines, and diagnostics being externally sourced—leaving countries vulnerable to global supply chain shocks. Health worker shortages persist, with only 2.3 professionals per 1,000 people (below the WHO’s recommended 4.45), and fewer than 30% of systems are digitized, undermining disease surveillance and early warning. Without decisive action, Africa CDC projects the continent could reverse two decades of health progress, face 2 to 4 million additional preventable deaths annually, and a heightened risk of a pandemic emerging from within. Furthermore, 39 million more Africans could be pushed into poverty by 2030 due to intertwined health and economic shocks. This is not just a sectoral crisis—it is an existential threat to Africa’s political, social, and economic resilience, and global stability. In response, African leaders, under Africa CDC’s stewardship, are advancing a comprehensive three-pillar strategy centered on domestic resource mobilization, innovative financing, and blended finance. more

Download (223)

View PDF (224)

Lista Nacional de Medicamentos Esenciales - Bolivia

Ministerio de Salud Bolivia (2022) C2

Lista Nacional de Medicamentos Esenciales

Download (125)

View PDF (131)

ENT y COVID-19

Pan American Health Organization (PAHO) Pan American Health Organization (PAHO) (2022) C_WHO

The webpage from the Pan American Health Organization (PAHO) discusses the heightened risk that individuals with noncommunicable diseases (NCDs)—such as cardiovascular diseases, diabetes, and cancer—face regarding severe illness and mortality from COVID-19. It emphasizes the necessity of informi... more

External Link

Фрамбезия : Основные факты

World Health Organization WHO (2022) C_WHO

Фрамбезия относится к группе хронических бактериальных инфекций, в совокупности называемых эндемическими трепонематозами. Возбудителями этих заболеваний, к кот�... more

Download (238)

View PDF (264)

Mpox Strategic Preparedness, Readiness, and Response Plan: Global Monitoring and Evaluation Framework

World Health Organization WHO Reliefweb OCHA Services (2022) C_WHO

This Mpox SPRP Global Monitoring & Evaluation (M&E) Framework, also referred to as the Framework, aims to monitor and report on global progress towards these objectives, including information about country-level response efforts and WHO support to Member States. Regular collection and analysis of da... more

Download (295)

View PDF (341)

Plan estratégico de respuesta a brotes de sarampión: 2021–2023: brotes de sarampión: prevención, preparación, respuesta y recuperación

World Health Organization WHO (2022) CC

External Link

PEN-Plus – Integrated chronic care for severe NCDs in poor, rural areas

NCDI Poverty Network (2022) CC

PEN-Plus is an integrated care delivery strategy focused on alleviating the noncommunicable disease (NCD) burden among the poorest children and young adults by increasing the accessibility and quality of chronic care services for severe NCDs – such as type 1 diabetes (T1D), rheumatic heart disease... more

Download (189)

View PDF (227)

Communication in neglected Tropical Diseases' elimination: A scoping review and call for action

Nieto-Sanchez C., Hatley DM, Gijalva MJ., et al. (2022) CC

PLoS Negl Trop Dis 16(10): e0009774. Although the practice of communication is often called upon when intervening asn involgvingcommunties affected by NTD's, the disciplinary framewokr of healt communication research has been largely absent from NTD strategies. To illustrate how practices conceptual... more

Download (181)

View PDF (189)

Public-private partnerships for health care infrastructure and services: considerations for policy makers in Ukraine

World Health Organization WHO, Regional Office of Europe (2022) C_WHO

ndependent of the current conflict, the health sector in Ukraine faces several critical shortcomings. In particular, the country has an oversupply of hospitals and an undersupply of primary care and diagnostic facilities. Addressing these limitations will require substantial amounts of capital inves... more

External Link

Posters and Factsheets Ebola Virus Disease

Centers for Disease Control and Prevention CDC (2022) CC

Poster for communities and health worker

External Link

Varíola dos macacos: Curso introdutório para contextos de surto africanos

World Health Organization (WHO) (2022) C_WHO

A varíola dos macacos é uma doença infeciosa emergente causada por um vírus transmitido aos humanos por animais infetados, na sua maioria roedores. Pode ser propagado a outras pessoas, mas a transmissão de pessoa para pessoa, isoladamente, não pode facilmente sustentar um surto. A apresentaç�... more

External Link

Antimicrobial Resistance (AMR): a Multidisciplinary Approach

London School of Hygien &Tropical Medicine (2022) C1

The course is aimed at those designing, implementing and evaluating strategies to address AMR. For example, the course would be relevant for members of National Action Plan committees, policy and practice professionals who are required to address and support AMR initiatives, mid-career scientists an... more

Download (229)

View PDF (272)

Plan de acción mundial para la seguridad del paciente 2021-2030: hacia la eliminación de los daños evitables en la atención de salud

World Health Organisation (WHO) (2022) C_WHO

En la actualidad, los daños que sufren los pacientes a causa de una atención poco segura constituyen un desafío importante y creciente para la salud pública mundial y son una de las principales causas de muerte y discapacidad en todo el mundo. La mayor parte de estos daños son evitables. Ahor... more

Download (375)

View PDF (312)

Care, cleaning and disinfection of pulse oximeters and patient monitors devices
recommended

World Health Organization WHO (2022) C_WHO

During monitoring and between patients Always read and follow the instructions and recommendations of the manufacturer`s manual The device must be cleaned and disinfected after each individual use and, at minimum weekly, prior to use on another patient.

Download (327)

View PDF (719)

Sprechstunde für Frauen und Mädchen mit Female Genital Mutilation in der Münchner Universitätsfrauenklinik rechts der Isar

C. von Saldern Bayerisches Ärzteblatt (2022) CC

Female Genital Mutilation (weibliche Genitalverstümmelung, FGM) ist ein globales Problem. Weltweit sind mehr als 200 Millionen Frauen und Mädchen betroffen. Davon lebten im Jahr 2020 ca. 75.000 in Deutschland. Viele der Betroffenen leiden unter FGM-bedingten Beschwerden und benötigen medizinisch... more

Download (131)

View PDF (190)

Information to guide individual health assessment of refugees fleeing the war in Ukraine - Considerations for healthcare workers

UNHCR; European Centre for Disease Prevention and Control ECDC, IOM; et al. (2022) C1

The war in Ukraine will have direct and indirect health consequences on conflict affected people, including internally displaced people and refugees. Governments in countries receiving refugees are providing them with access to healthcare. This document aims to provide information to guide individua... more

External Link

Clinical Profile and Management of Patient Patients with Ischemic Heart Disease and/or Peripheral Artery Disease in Clinical Practice: The APALUSA Study

Barrios, V.; Escobar, C.; Suarez C. et al. Journal of Clinical Medicine (2022) CC

This study was aimed to ascertain the clinical profile and management of patients with ischemic heart disease (IHD) and/or peripheral artery disease (PAD). In this observational and cross-sectional study developed in 80 hospitals throughout Spain, consecutive adults with stable IHD and/or PAD were i... more

Care, cleaning and disinfection of pulse oximeters and patient monitors devices recommended

Care, cleaning and disinfection of pulse oximeters and patient monitors devices
recommended